Kymera IPO Presentation Deck

Robust Pipeline of Targeted Protein Degraders for Un-drugged Targets Pathway IL-1R/TLR JAK/STAT Program IRAKA KYMERA IRAKIMID (IRAKA, Ikaros, Alolos) STAT3 Indication(s) HS, AD, RA MYD-88MT DLBCL Liquid & Solid Tumors Discovery Pre-Clinical KT-474 Phase 1 Phase 2 - Oncology = Inflammation/Immunology "Kymera will have the option to participate equally in the development of Sanofi-partnered programs in the US during clinical development Phase 3 Next Milestone Ph1: 1H 21 Ph1: 2H '21 Ph1: 2H '21 Leveraging the capabilities of our Pegasus platform, we are also advancing: • Multiple wholly-owned degrader programs in immunology-inflammation and genetically defined oncology indications . Multiple programs across several disease indications with our partners: Vertex and Sanofi Rights KYMERA SANOFI KYMERA KYMERA

View entire presentation